Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


T cell renaissance in COVID-19


This preprint identifies 1,739 and 1,591 SARS-CoV-2-derived peptides that bind to HLA-A/B/C or HLA-DR, respectively, from 180 SARS-CoV-2 convalescent donors and 185 healthy controls. Nelde et al. show that convalescent donors have T cell responses to multiple SARS-CoV-2 epitopes, with a predominant IFNγ+CD8+ T cell response to HLA-A/B/C-binding peptides but a multifunctional (IFNγ+TNF+CD107a+) CD4+ T cell response to HLA-DR-binding peptides. Some donors had T cell responses but not antibodies, which highlights the potential importance of T cells in COVID-19 vaccine development. IgG responses were associated with severe cases, whereas those with diverse T cell responses had milder disease. Cross-reactive T cell responses to 31% of HLA-A/B/C-binding epitopes and to 70% of HLA-DR-binding epitopes were detected in unexposed individuals, supporting the potential existence of heterologous immunity.


Original article

  1. Nelde, A. et al. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition. Preprint at Research Square (2020)

    Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Lee Garner or Liliana Cifuentes.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Garner, L., Cifuentes, L. T cell renaissance in COVID-19. Nat Rev Immunol 20, 518 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing